Astrazeneca (AZN)


AZN Share PerformanceMore

52 week high5,505.0 05/08/16
52 week low3,680.0 24/06/16
52 week change 310.5 (7.34%)
4 week volume53,976,933 22/12/16

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

AZ expands lung cancer programme

AstraZeneca has issued an update on its immuno-oncology late-stage clinical development programme in first-line non-sm...

AZ 1st-line lung cancer immuno-oncology programme

RNS Number: 3289U AstraZeneca PLC 17 January 2017 17 January 2017 07:00 ASTRAZENECA EXPANDS 1ST-LINE LUNG CANCER IMMUNO-ONCOLOGY PROGRAMME OPPORTUNITIES Refined endpoints and statistical analysis plan in the Phase III MYSTIC trial China regulatory submission opportunity strengthened with the expansion of the Phase III NE...

Broker Forecast - JP Morgan Cazenove issues a broker note on AstraZeneca PLC

JP Morgan Cazenove today reaffirms its neutral investment rating on AstraZeneca PLC (LON:AZN) and cut its price targ...

Total Voting Rights

RNS Number: 2324T AstraZeneca PLC 03 January 2017 3 January 2017 16:00 Transparency Directive Voting Rights and Capital The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. On 31 December 2016 the issued share capital of AstraZeneca PLC with voting rights is 1,265,229,424 ordina...

Chart of the week: New target for this stock

Using his handy and simple method of market analysis and forecasting, ex-NASA scientist John Burford has spotted upsid...

FTSE 100 flat as HSBC drags

The blue chip index was flat at 7,057 as bank disputes with the US Department of Justice and a weak trading session in Asi...

AstraZeneca completes sale of certain rights to Pfizer

AstraZeneca completed its agreement with Pfizer for the sale of commercialisation and development rights to its late-stage...

Broker Forecast - Kepler Cheuvreux issues a broker note on AstraZeneca PLC

Kepler Cheuvreux today initiates coverage of AstraZeneca PLC (LON:AZN) with a buy investment rating and price target...

Latest discussion posts More

  • Re: Trump again

    Notice I specifically didn't express an opinion either way.
  • Astra and the MYSTIC trial

    AstraZeneca has issued an update on its immuno-oncology late-stage clinical development programme in first-line non-small cell lung cancer, including a refinement of the Phase ...
    Proverbs 26 vs 5
  • Re: Trump again

    BBC talking about impeachment tonight!

Users' HoldingsMore

Users who hold Astrazeneca also hold..
RDS 'B'33%

Codes & Symbols